Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$55.88 USD
-0.19 (-0.34%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $56.00 +0.12 (0.21%) 4:56 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 301 - 311 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q3:10 Earnings a Non-Event, Focus Remains on Full ALS Data in December
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Reports Q2:10 Earnings and Provides Update to CK-?357 and omecamtiv mecarbil Programs
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Initiates CK-?357 Peripheral Artery Disease and Claudication Phase IIa Study
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Q1:10 Earnings and Update to CK-?357 Studies and omecamtiv mecarbil Studies
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
CYTK Announces Statistically Significant Results from the CK-20173537 Phase I Trial
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G